Beijing Wantai Biological Pharmacy Enterprise (SHA:603392) received approval from China's National Medical Products Administration for its self-developed freeze-dried recombinant respiratory syncytial virus vaccine, according to a Tuesday filing with the Shanghai bourse.
The vaccine prevents lower respiratory tract disease caused by respiratory syncytial virus in vulnerable populations such as the elderly and those with chronic diseases.